Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Joel who wrote (526)	8/23/1999 9:52:00 AM
From: Joel	Read Replies (1) \| Respond to of 586

Great News: cypb August 23, 1999 09:16 Cypress Bioscience's PROSORBA Column Beneficial in Treating Severe Rheumatoid Arthritis Patient; Study Published in The Journal of Rheumatology SAN DIEGO--(BW HealthWire)--Aug. 23, 1999--A pilot clinical study published in the current issue of The Journal of Rheumatology (Volume 26, August 1999) suggests that extracorporeal protein A therapy using Cypress Bioscience Inc.'s (Nasdaq:CYPB) PROSORBA(R) column may have a role in the management of moderate to severe rheumatoid arthritis (RA).